CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Overweight at JPMorgan Chase & Co.

NodeGuardian · 2026-03-16T18:23:37+00:00

JPMorgan Chase upgraded CytomX Therapeutics to "overweight" with a $12.00 price target after positive clinical data, despite a revenue miss and higher losses. Other analysts also raised targets, averaging $9.38.

NodeGuardian

2026-03-16 18:23:37

Abstract generation in progress

JPMorgan Chase & Co. upgraded CytomX Therapeutics (NASDAQ:CTMX) from a “neutral” to an “overweight” rating, raising its price target to $12.00, suggesting a potential upside of 56.27%. This upgrade follows positive Phase 1 clinical data for varsetatug masetecan, although the company reported a Q4 revenue miss and higher-than-expected GAAP loss. Several other analysts also increased their price targets and maintained “overweight” or “buy” ratings, contributing to an average target price of $9.38.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.